New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2012
08:03 EDTOGXIOncoGenex reports positive data for compound OGX-427
OncoGenex announced that preclinical data utilizing their pipeline compound OGX-427 was presented at the 27th Annual EAU Congress.This preclinical study, along with previously reported preclinical data, further demonstrated the potential of OGX-427 to augment anti-cancer therapies and delay tumor progression. The study showed that when Hsp27 was decreased via OGX-427 treatment, the effect of the Hsp90 inhibitors was enhanced and tumor cell death was observed. The authors concluded OGX-427 in combination with Hsp90 inhibitors potentiated the effects of Hsp90, delayed tumor growth and prolonged survival in murine prostate cancer models.
News For OGXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:21 EDTOGXIOncoGenex Phase 2 Borealis-1 trial resulted in 50% reduction in risk of death
OncoGenex Pharmaceuticals announced results from the randomized, controlled Phase 2 Borealis-1 trial evaluating low and high dose apatorsen in combination with gemcitabine/cisplatin chemotherapy compared to chemotherapy alone in the treatment of metastatic bladder cancer. Overall trial results indicated that the addition of 600mg apatorsen to standard of care chemotherapy showed a 14% reduction in risk of death and a 17% reduction in progressive disease and death when compared to chemotherapy alone. Over one-third of the patients in the trial had lower performance status, as defined by a Karnofsky score of 80 percent or less. These patients derived the greatest benefit from 600mg apatorsen in combination with chemotherapy, resulting in a 50% reduction in risk of death compared to chemotherapy alone. Less benefit was observed in the 1000mg apatorsen arm due to increased adverse events leading to a higher rate of discontinuation of both apatorsen and chemotherapy. Apatorsen 600mg was well tolerated in combination with chemotherapy.
December 16, 2014
06:37 EDTOGXIOncoGenex completes patients enrolment for Rainier clinical trial
Subscribe for More Information
December 12, 2014
16:13 EDTOGXIBiotechnology Value Fund reports 6.43% passive stake in OncoGenex

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use